CRISPR Therapeutics AG is widely recognized as a premier industry leader in the commercialization of CRISPR technology, having successfully achieved historic regulatory milestones by winning approvals for the world's first gene-editing medicine. Other leading pioneers include Editas Medicine, Beam Therapeutics, and Intellia Therapeutics, all of which compete fiercely in developing advanced clinical-stage human gene therapies.